Non-Viral Delivery of RNA Gene Therapy to the Central Nervous System

被引:9
作者
Hauck, Ellen S. [1 ]
Hecker, James G. [2 ]
机构
[1] Temple Univ, Lewis Katz Sch Med, Dept Anesthesiol, 3401 N Broad St, Philadelphia, PA 19140 USA
[2] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, POB 359724,329 Ninth Ave, Seattle, WA 98104 USA
关键词
non-viral; lipid-mediated; gene delivery; transfection; RNA; DNA; siRNA; neurons; post-mitotic; molecular therapy; transient; CHO; IN-VIVO; CATIONIC LIPIDS; SIRNA DELIVERY; DNA; TRANSFECTION; EXPRESSION; BRAIN; NANOPARTICLES; LIPOPLEXES; EFFICIENT;
D O I
10.3390/pharmaceutics14010165
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Appropriate gene delivery systems are essential for successful gene therapy in clinical medicine. Lipid-mediated nucleic acid delivery is an alternative to viral vector-mediated gene delivery and has the following advantages. Lipid-mediated delivery of DNA or mRNA is usually more rapid than viral-mediated delivery, offers a larger payload, and has a nearly zero risk of incorporation. Lipid-mediated delivery of DNA or RNA is therefore preferable to viral DNA delivery in those clinical applications that do not require long-term expression for chronic conditions. Delivery of RNA may be preferable to non-viral DNA delivery in some clinical applications, since transit across the nuclear membrane is not necessary, and onset of expression with RNA is therefore even faster than with DNA, although both are faster than most viral vectors. Delivery of RNA to target organ(s) has previously been challenging due to RNA's rapid degradation in biological systems, but cationic lipids complexed with RNA, as well as lipid nanoparticles (LNPs), have allowed for delivery and expression of the complexed RNA both in vitro and in vivo. This review will focus on the non-viral lipid-mediated delivery of RNAs, including mRNA, siRNA, shRNA, and microRNA, to the central nervous system (CNS), an organ with at least two unique challenges. The CNS contains a large number of slowly dividing or non-dividing cell types and is protected by the blood brain barrier (BBB). In non-dividing cells, RNA-lipid complexes demonstrated increased transfection efficiency relative to DNA transfection. The efficiency, timing of the onset, and duration of expression after transfection may determine which nucleic acid is best for which proposed therapy. Expression can be seen as soon as 1 h after RNA delivery, but duration of expression has been limited to 5-7 h. In contrast, transfection with a DNA lipoplex demonstrates protein expression within 5 h and lasts as long as several weeks after transfection.
引用
收藏
页数:16
相关论文
共 61 条
[1]   Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis [J].
Adams, D. ;
Gonzalez-Duarte, A. ;
O'Riordan, W. D. ;
Yang, C. -C. ;
Ueda, M. ;
Kristen, A. V. ;
Tournev, I. ;
Schmidt, H. H. ;
Coelho, T. ;
Berk, J. L. ;
Lin, K. -P. ;
Vita, G. ;
Attarian, S. ;
Plante-Bordeneuve, V. ;
Mezei, M. M. ;
Campistol, J. M. ;
Buades, J. ;
Brannagan, T. H., III ;
Kim, B. J. ;
Oh, J. ;
Parman, Y. ;
Sekijima, Y. ;
Hawkins, P. N. ;
Solomon, S. D. ;
Polydefkis, M. ;
Dyck, P. J. ;
Gandhi, P. J. ;
Goyal, S. ;
Chen, J. ;
Strahs, A. L. ;
Nochur, S. V. ;
Sweetser, M. T. ;
Garg, P. P. ;
Vaishnaw, A. K. ;
Gollob, J. A. ;
Suhr, O. B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :11-21
[2]   Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: Methods and evidence for nonviral mRNA gene delivery to the central nervous system [J].
Anderson, DM ;
Hall, LL ;
Ayyalapu, AR ;
Irion, VR ;
Nantz, MH ;
Hecker, JG .
HUMAN GENE THERAPY, 2003, 14 (03) :191-202
[3]   Cytoplasmic transport and nuclear import of plasmid DNA [J].
Bai, Haiqing ;
Lester, Gillian M. Schiralli ;
Petishnok, Laura C. ;
Dean, David A. .
BIOSCIENCE REPORTS, 2017, 37
[4]   Biological barriers to cellular delivery of lipid-based DNA carriers [J].
Bally, MB ;
Harvie, P ;
Wong, FMP ;
Kong, S ;
Wasan, EK ;
Reimer, DL .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 38 (03) :291-315
[5]   Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I [J].
Belur, Lalitha R. ;
Temme, Alexa ;
Podetz-Pedersen, Kelly M. ;
Riedl, Maureen ;
Vulchanova, Lucy ;
Robinson, Nicholas ;
Hanson, Leah R. ;
Kozarsky, Karen F. ;
Orchard, Paul J. ;
Frey, William H., II ;
Low, Walter C. ;
McIvor, R. Scott .
HUMAN GENE THERAPY, 2017, 28 (07) :576-587
[6]   Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA [J].
Blakney, Anna K. ;
McKay, Paul F. ;
Yus, Barbara Ibarzo ;
Aldon, Yoann ;
Shattock, Robin J. .
GENE THERAPY, 2019, 26 (09) :363-372
[7]   siRNA delivery using polyelectrolyte-gold nanoassemblies in neuronal cells for BACE1 gene silencing [J].
Chaudhary, Aparna ;
Garg, Sanjeev .
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2017, 80 :18-28
[8]   Gene Carriers and Transfection Systems Used in the Recombination of Dendritic Cells for Effective Cancer Immunotherapy [J].
Chen, Yu-Zhe ;
Yao, Xing-Lei ;
Tabata, Yasuhiko ;
Nakagawa, Shinsaku ;
Gao, Jian-Qing .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2010,
[9]   Transfection types, methods and strategies: a technical review [J].
Chong, Zhi Xiong ;
Yeap, Swee Keong ;
Ho, Wan Yong .
PEERJ, 2021, 9
[10]   Lipid Nanoparticle Systems for Enabling Gene Therapies [J].
Cullis, Pieter R. ;
Hope, Michael J. .
MOLECULAR THERAPY, 2017, 25 (07) :1467-1475